

Title (en)
IMMUNE POTENTIATING COMPOSITIONS

Title (de)
IMMUNSYSTEM STEIGERENDE ZUSAMMENSETZUNGEN

Title (fr)
COMPOSITIONS POTENTIALISATRICES IMMUNES

Publication
EP 1313839 B1 20140319 (EN)

Application
EP 01931205 A 20010517

Priority
• AU 0100565 W 20010517
• AU PQ755300 A 20000517

Abstract (en)
[origin: WO0188097A1] A composition of matter is disclosed, comprising an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) for a time and under conditions sufficient to enhance the antigen presenting function of said cells. Also disclosed are immunopotentiating compositions and their use for treatment and/or prophylaxis of a disease or condition.

IPC 8 full level
C12N 5/07 (2010.01); **C12N 15/09** (2006.01); **A61K 39/00** (2006.01); **A61K 39/002** (2006.01); **A61K 39/02** (2006.01); **A61K 39/12** (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 31/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **C12N 5/09** (2010.01); **C12N 5/10** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01); **A61K 35/12** (2006.01)

CPC (source: EP US)
A61K 39/0011 (2013.01 - EP US); **A61K 39/4611** (2023.05 - EP); **A61K 39/464411** (2023.05 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **C12N 5/0693** (2013.01 - EP US); **A61K 35/12** (2013.01 - EP US); **C12N 2501/24** (2013.01 - EP US); **C12N 2501/51** (2013.01 - EP US); **C12N 2501/58** (2013.01 - EP US)

Citation (examination)
• DENFELD RALF W ET AL: "In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor immunity", INTERNATIONAL JOURNAL OF CANCER, vol. 62, no. 3, 1995, pages 259 - 265, ISSN: 0020-7136
• MORANDINI R ET AL: "Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanocytes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 175, no. 3, June 1998 (1998-06-01), pages 276 - 282, ISSN: 0021-9541
• STURMHOFEL K ET AL: "POTENT ACTIVITY OF SOLUBLE B7-IGG FUSION PROTEINS IN THERAPY OF ESTABLISHED TUMORS AND AS VACCINE ADJUVANT", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 59, no. 19, 1 October 1999 (1999-10-01), pages 4964 - 4972, XP000941780, ISSN: 0008-5472
• MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650 - 2656, XP002154490, ISSN: 0008-5472

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0188097 A1 20011122; AU PQ755300 A0 20000608; CA 2408756 A1 20011122; CA 2408756 C 20141209; EP 1313839 A1 20030528; EP 1313839 A4 20060125; EP 1313839 B1 20140319; JP 2003533539 A 20031111; JP 4943621 B2 20120530; US 2004235156 A1 20041125; US 2009081792 A1 20090326; US 7455846 B2 20081125; US 7964400 B2 20110621

DOCDB simple family (application)
AU 0100565 W 20010517; AU PQ755300 A 20000517; CA 2408756 A 20010517; EP 01931205 A 20010517; JP 2001585305 A 20010517; US 25919408 A 20081027; US 27664203 A 20030630